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APC = antigen presenting cell; IL = interleukin; MHC = major histocompatibility complex; TCR = T-cell receptor; TGF-β = transforming growth
factor beta; Th = T helper cell; Tr1 = T regulatory 1; TR = CD4+CD25+ T regulatory cell.
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Introduction
The ability of the immune system to distinguish between
self-antigens and nonself-antigens, and between harmful
and innocuous foreign antigens, is critical to the
maintenance of immune homeostasis. Failure to maintain
tolerance to self-antigens or innocuous antigen results in
the development of autoimmune or allergic disease,
respectively. To achieve this state of immune tolerance,
the immune system has evolved a variety of mechanisms.
These include deletion of self-reactive clones in the
thymus through a process referred to as negative
selection, or central tolerance [1]. Central tolerance is
imperfect, however, and self-reactive T cells do appear in
the periphery. Likewise, the immune system is
continuously distinguishing between innocuous and
pathogenic foreign antigens.
To deal with these situations the immune system has
evolved a system of induced peripheral tolerance. Two
well-characterized mechanisms of peripheral tolerance are
the death of self-reactive T cells via negative selection and
the induction of a state of nonresponsiveness, or anergy
[2]. A third, less well-characterized, mechanism is the
active suppression of T-cell responses. This latter
mechanism involves a recently described T-cell subset,
known as regulatory T cells, which are induced in the
periphery in an antigen-specific fashion [3,4]. The present
review will discuss the various types of regulatory T cells,
as well as the mechanisms that have been described for
their generation.
Natural versus acquired regulatory T cells
Several classes of regulatory T cells, capable of
suppressing antigen-specific immune responses, have
been identified and characterized. These subsets can be
distinguished in a variety of ways; including whether
suppression is cell-contact mediated or is mediated
through soluble factors such as IL-10 and transforming
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Abstract
The immune system has evolved a variety of mechanisms to achieve and maintain tolerance both
centrally and in the periphery. Central tolerance is achieved through negative selection of
autoreactive T cells, while peripheral tolerance is achieved primarily via three mechanisms: activation-
induced cell death, anergy, and the induction of regulatory T cells. Three forms of these regulatory T
cells have been described: those that function via the production of the cytokine IL-10 (T regulatory 1
cells), transforming growth factor beta (Th3 cells), and a population of T cells that suppresses
proliferation via a cell-contact-dependent mechanism (CD4+CD25+ TR cells). The present review
focuses on the third form of peripheral tolerance — the induction of regulatory T cells. The review will
address the induction of the three types of regulatory T cells, the mechanisms by which they
suppress T-cell responses in the periphery, the role they play in immune homeostasis, and the
potential these cells have as therapeutic agents in immune-mediated disease.
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growth factor beta (TGF-β). These cells can also be
distinguished based on where they originate, in the
thymus or in the periphery.
One prevailing model is that a class of regulatory T cells
that originate in the thymus, are self-reactive and are
involved in protection from autoimmune responses [5].
This class of cells referred to as ‘natural’ T regulatory cells
(TR) are characterized by the expression of the IL-2
receptor  α-chain (CD25), and more recently by the
forkhead/winged-helix transcription factor FoxP3 [6–9].
These TR have the ability to suppress the activation of
conventional T cells in a cell-contact-dependent, IL-10-
independent and TGF-β-independent, manner [10,11]. On
the other hand, ‘acquired’ regulatory T cells arise in the
periphery, either during an immune response or after
encountering a tolerogenic dendritic cell. These regulatory
T cells are believed to differentiate from naïve precursors
and are specific for antigens not presented in the thymus,
such as food antigens, bacterial flora, pathogens, and self-
antigens such as insulin [3]. They suppress the activation
of conventional T cells in a cytokine-dependent manner:
TGF-β for Th3 cells, and IL-10 for T regulatory 1 (Tr1)
cells (Table 1) [4,12,13].
Recent work has shown that this distinction between
natural and acquired Tregs may be simplistic. As
discussed in the following, Tregs with the properties of
CD4+CD25+ (TR) have been shown to be generated in
vitro and in vivo in systems using both self-antigens and
foreign antigens. The present review will summarize the
recent findings on the development of acquired Tregs, and
on their potential function in regulating immune responses
to both self-antigens and foreign antigens.
Th3 cells
It has long been recognized that the oral administration of
antigen can lead to immunological tolerance to that
antigen. Recent work has begun to shed light on the
mechanisms that underlie this process. Oral tolerance is
established in the gut-associated lymphoid tissue, which
consists of Peyer’s patches, intraepithelial lymphoid cells,
and scattered lymphoid cells in the lamina propria. Several
lines of evidence have shown that oral tolerance is an
active, ongoing process. For example, a high antigen dose
leads to hyporesponsiveness mediated by anergy or
deletion [14,15]. On the other hand, low doses of antigen
lead to the generation of Th2 cells, as well as to active
suppression through the generation of antigen-specific
regulatory T cells known as Th3 cells [16].
Th3 cells produce TGF-β, but differ from classical Th2
cells in that TGF-β expression does not always correlate
with IL-4 or IL-10 expression [12]. Importantly, these Th3
cells have been shown to transfer tolerance in vivo, and to
suppress antigen-specific responses in vitro [16]. In both
cases the suppression is mediated by TGF-β. Further
support for the role of TGF-β in regulating immune
responses comes from studies using mice that lack the
ability to either produce or respond to TGF-β. In both
instances the mice develop a fatal autoimmune
lymphoproliferative disease [17]. As these mice have
normal CD4+CD25+ TR cells (see later), these data
suggest that a defect in either Th3 or Tr1 cells is
responsible for the observed autoimmunity [17,18].
Tr1 cells
In addition to TGF-β, IL-10 has been shown to be a potent
immunoregulatory cytokine [13,19]. The mechanism by
which IL-10 regulates immune responses involves both
T cells and antigen presenting cells (APCs). IL-10
treatment of dendritic cells results in the downmodulation
of the co-stimulatory molecules CD80 and CD86, as well
as MHC class II, and decreases the ability of these
dendritic cells to activate T cells [20,21]. IL-10 can also
have direct effects on CD4+ T cells. Constant antigen
stimulation of T cells in the presence of IL-10, either in the
presence or the absence of APCs, results in anergy
[20,22–24]. Unlike other anergic CD4+ T cells, however,
anergy in IL-10-treated T cells is not reversed by the
addition of IL-2 or IL-15 [23]. When these IL-10-anergized
T cells are driven to proliferate, they have a unique
cytokine expression profile, producing high amounts of IL-
10 and TGF-β, lesser amounts of interferon gamma, and
no IL-2 or IL-4 [13,22]. CD4+ T cells with this phenotype
are referred to as Tr1 cells.
Table 1
Cytokine expression profiles of the three classes of regulatory T cells
Cytokine expressed Th3 cells T regulatory 1 cells CD4+CD25+ TR cells
Interferon gamma +/– + –
IL-4 +/– – –
Transforming growth factor beta +++ ++ +/–
IL-10 +/– +++ +/–
The production of cytokine is indicated as absent (–) or present (+) with relative quantities of cytokine indicated by +/– < + < ++ < +++.217
In spite of the fact that Tr1 cells have poor proliferative
capabilities, they express normal levels of T cell activation
markers, including CD25, CD40L, and CD69, following
TCR stimulation [20]. Tr1 cells have been shown to
regulate immune responses both in vitro and in vivo. For
example, co-culture of Tr1 cells with freshly isolated CD4+
T cells in the presence of allogeneic APCs results in the
suppression of the proliferative allo-response [25,26].
Neutralization of IL-10 and/or TGF-β reverses this
suppression [22]. Tr1 cells have also been shown to be
capable of suppressing antibody production by B cells
[27], and to decrease the ability of monocytes and
dendritic cells to act as APCs. Kemper and colleagues
[28] very recently showed that human Tr1 cells can be
derived by stimulating CD4+ T cells through co-
engagement of CD3 and the complement regulator CD46
in the presence of IL-2. These conditions resulted in IL-10-
producing cells capable of inhibiting the activation of
bystander T cells. Unlike the Tr1 cells described earlier,
CD3/CD46-generated Tr1 cells exhibited strong and
prolonged proliferation when stimulated. There thus
appear to be multiple pathways capable of producing IL-
10 secreting regulatory T cells.
Tr1 cells also have potent effects on in vivo immune
responses. Studies with allograft systems have shown that
long-term graft tolerance correlates with the presence of
CD4+ T cells that suppress naïve T cells via IL-10 and
TGF-β [29–31]. In mouse systems, CD4+ T cells with Tr1-
like properties have been isolated following tolerance
induction to allergens [32,33], as well as in models of
autoimmunity [34,35] and in response to infectious
pathogens [36,37].
As already described, IL-10-treated dendritic cells are
capable of driving the generation of Tr1 cells in vitro.
However, the nature of the in vivo dendritic cell subset
responsible for Tr1 cell differentiation remains unclear.
Several groups have isolated specific dendritic cell
subsets from nonlymphoid peripheral tissues that are
capable of inducing tolerance. These subsets have been
isolated from a variety of tissues, including the liver, the
lung, and the intestine, and they appear to function via IL-
10 secretion [32,38–40]. Wakkach and colleagues [41]
recently identified a subset of dendritic cells in the spleen
and lymph node that appear to be a natural tolerizing
dendritic cell subset. The cells have a plasmacytoid
morphology and remain immature even after in vitro
activation with lipopolysaccharide or CpG, they have an
unusual cell-surface phenotype (CD11clo/CD45RBhi), and
they produce large amounts of IL-10 when stimulated.
These cells are capable of directly generating Tr1 cells in
vitro and in vivo, and may represent a naturally occurring
dendritic cell subset involved in eliciting tolerance in vivo
[41]. The identification of this dendritic cell subset, as well
as the demonstration that Tr1 cells can regulate immune
responses in vivo, thus enhances the possible therapeutic
uses of Tr1 cells as a means to regulate immune
responses in a variety of diseases.
CD4+CD25+, cell-contact-dependent TR cells
A third regulatory T cell population has been identified,
which is characterized by the expression of the cell
surface markers CD4 and CD25 (referred to as TR cells).
These CD25+CD4+ (TR) cells are anergic, but upon
activation suppress the proliferation and IL-2 production of
naive and memory CD4+ T cells through a contact-
dependent, cytokine-independent mechanism [10].
In mice, TR cells are thought to represent a population of
T cells that are thymically derived and suppress
autoreactive CD4+ T cells. This is supported by the finding
that thymectomy of mice at day 3 of life leads to a lack of
TR cells and produces a spectrum of spontaneous organ-
specific autoimmune manifestations including autoimmune
gastritis, oophoritis, orchitis, and thyroiditis [42]. Mice that
have undergone thymectomy are rescued by the infusion
of CD4+CD25+ T cells [43,44], and the removal of
CD4+CD25+ using depleting antibody leads to a similar
autoimmune phenotype seen in mice after thymectomy
[45]. Studies of experimental autoimmune encephalo-
myelitis have demonstrated the protective effect of these
regulatory cells in the response to inflammation directed
against self-antigens [46], and additional studies of
thyroiditis [47], diabetes [48], and nerve injury [49] have
suggested that the TR responses are specific for self-
antigens. It is thought that TR cells in mice represent those
thymocytes with the highest affinity for self-peptide but
that are below the threshold of negative selection [50].
Only a small number of TR cells are thus selected, all of
which are more sensitive to self-antigens than other
circulating autoreactive T cells.
The molecular basis for the development and function of
TR cells remains unclear. Work in mice with targeted
mutations suggests a role for several molecules in the
development and function of TR cells. One gene clearly
associated with the development and function of TR cells
is FoxP3. Mice carrying the X-linked scurfy mutation
develop a lymphoproliferative disease, display a multi-
organ autoimmune disease, and lack conventional
CD4+CD25+ TR cells [6,7,51–53]. In mice, FoxP3 has
been shown to be expressed exclusively in CD4+CD25+
TR cells and is not induced upon activation of CD25–
T cells. When FoxP3 is introduced via retrovirus or
enforced transgene expression, however, naive
CD4+CD25– T cells are converted to TR cells [8]. Thus, in
mice, FoxP3 is both necessary and sufficient for the
development and function of CD4+CD25+ TR cells.
TR cells with properties similar to those described in the
mouse are present in humans. These cells represent
Available online http://arthritis-research.com/content/6/5/215218
1–3% of all CD4+ T cells and require activation to induce
suppressor function, which is mediated via cell–cell
contact, and is abrogated by the addition of IL-2 [54,55].
In humans, TR cells have been shown to regulate T-cell
responses to both foreign antigen and self-antigen [56],
including TR cells specific for alloantigens [57]. TR cells in
humans, as in mice, express FoxP3 [58], and individuals
with a mutation in the FoxP3 gene develop
immunodysregulatory, polyendocrinopathy, enteritis X
linked syndrome, a disease similar to that seen in scurfy
mice [59].
However, the source of the CD4+CD25+ TR cells found in
the peripheral blood of humans, whether thymic or
peripheral, is not known. CD4+CD25+ TR cells have been
identified in the human thymus [60], and TR cells with a
naïve phenotype have been identified in cord blood [61].
Those TR cells isolated from adult peripheral blood are
CD4+CD25+ CD45RO+ CD45Rblow [62] and have a
short telomere length, however, both of which suggest
that this population of TR cells is thought to be derived
from highly differentiated memory cells [56].Yet, in
humans, it is impossible to prove whether the TR cells
isolated from peripheral blood originate in the thymus, and
are expanded in the periphery, or whether they have been
generated in the periphery. The possibility exists that, due
to differences between mouse and man in life expectancy,
thymic involution, and antigen exposures, the development
of CD4+CD25+ TR cells may occur in the periphery in
man.
Induction of CD4+CD25+ TR cells in the
periphery
The induction of TR cells that resemble the ‘natural’ or
thymically derived TR cells described in mice has been
described in man. The induction is based upon the ability
to create CD4+CD25+ T cells from nonregulatory cells
that suppress proliferation of T cells in a contact-
dependent, cytokine-independent manner. In all cases,
although the conditions under which these cells are
induced differ, activation of CD4+ T cells is required to
generate a TR cell. Both in vivo and in vitro studies in mice
support the idea that these cells can arise outside of the
thymus. TR cells have been identified in the periphery of
mice under conditions that do not favor TR cell
development in the thymus [63]. The administration of
oral, subcutaneous, intravenous antigen [64–66] or a
repeated [67–70] exposure to superantigen [67] have
been reported to induce CD4+CD25+ TR cells in the
periphery of mice.
Induction of TR cells from peripheral CD4+CD25– T cells
in vitro has been reported by several groups. Duthoit and
colleagues have demonstrated that recently activated T
cells (4 days post stimulation) are anergic, express FoxP3,
and suppress the proliferation of naïve T cells via a cell-
contact-dependent mechanism in co-culture experiments
[68]. Additionally, in vitro induction of TR cells by
activation of CD4+CD25– T cells in the presence of TGF-
β has been reported by two groups [69,70]. In the most
recent of these reports, Chen and colleagues have shown
that the induction of both FoxP3 expression and TR cell
function in previously nonregulatory CD4+CD25– T cells
required both TCR activation and TGF-β exposure [70].
However, Piccirillo and colleagues [66] have found that TR
cell function is normal in the absence of either TGF-β
production or responsiveness. We have also shown that T
cells from mice expressing a T-cell-specific transgene
encoding a dominant-negative TGF-βRII have normal
levels of FoxP3 (K Newton, SF Ziegler, unpublished data).
In humans, CD4+CD25+ T cells with regulatory activity
requiring only cell–cell contact have been induced via
activation under several different conditions. Taams and
colleagues [56] used T-cell clones to demonstrate that
activation of these clones with peptide only, in the
absence of co-stimulation, leads to T cells that are anergic
and suppress proliferation of other T-cell clones via cell
contact [56]. TR cells specific to allogeneic antigens have
been generated in vitro by activation with IL-10-treated
allogeneic dendritic cells [20]. Induction of TR cells from
CD4+CD25– T cells has also been successful by
activation of CD4+CD25– T cells with mature, allogeneic
dendritic cells, and these T cells also expressed FoxP3.
The specificity of the TR cells was determined by the type
of mature dendritic cells used: autologous dendritic cells
generate TR specific for self-antigens [71], and allogeneic
dendritic cells produce alloreactive TR cells (MR Walker,
JH Buckner, SF Ziegler, unpublished data).
The induction of CD4+CD25+ TR cells in the absence of
APCs has also been achieved in vitro. Our group has
recently demonstrated that activation of CD4+CD25– T
cells with plate-bound anti-CD3 and soluble anti-CD28
can induce a group of CD4+CD25+ T cells with regulatory
function that express FoxP3. These TR cells are derived
from highly purified CD4+CD25– cells; they become
CD25+FoxP3+ within 4 days of activation and regulate in a
contact-dependent, cytokine-independent manner. The
function and cell surface markers of these cells are
indistinguishable from the CD4+CD25+ T cells directly
isolated from the peripheral blood that have been defined
as ‘natural’ TR cells [58]. Unlike that reported in the
mouse, induction of FoxP3 in this system does not require
the presence of TGF-β. However, the induction does
require engagement of the TCR and co-stimulation
through CD28. Similarly, induction of TR cells with mature
dendritic cells also required MHC II and CD80/86 co-
stimulation to induce TR cells [71]. The induction of TR
cells  in vitro has also been shown using αCD3 and a
novel antibody 4C8 [72] or exposure to staphylococcal
enterotoxin B for 7 days in culture [67].
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Each of these systems used to induce TR cells have
differences; however, several common factors are present.
TR cells can be generated from peripheral CD4+CD25–
T cells, but only in response to activation. The activation
conditions required for that induction might differ between
mouse and man. However, differences in culture
conditions and assays used to measure suppression make
these comparisons difficult, and more work is needed to
clarify these apparent differences. For example,
differences between the species in the expression of
surface molecules on T cells may contribute. Human T
cells, unlike those from rodents, express HLA class II and
co-stimulatory molecules upon activation, which may allow
induction of TR cells to occur in the absence of an APC. In
addition, if the differentiation and function of TR cells are
regulated by the expression of FoxP3 then, as the
regulation of FoxP3 expression becomes better
understood, the requirements for TR cell induction will
become more apparent and the differences between
mouse and man will be better understood.
Our ability to generate TR cells in the periphery suggests a
larger question: Do TR cells represent a lineage of T cells
or a state of activation that may be achieved by any T cell
under the appropriate conditions of activation? The
induction of TR cells in the periphery allows for a dynamic
immune response when the body is threatened by
infection or injury. In this setting T cells will become
activated, and will recruit other T cells and other
inflammatory cells and mediators to the site. As the
response becomes mature, a group of regulatory T cells
will develop locally as a result of the local milieu allowing
for a resolution of inflammation and regulating the
responses directed to self-antigens exposed during the
inflammatory response.
Role of peripherally generated TR cells in the
immune response to foreign antigens
Regulation of immune responses is required to protect
individuals from autoreactive T cells that have escaped
into the periphery. Regulation of autoreactivity is present
at the level of thymic selection, but also in the periphery.
Those autoreactive cells that escape negative selection
must be restrained in the periphery, and it is thought that
CD4+CD25+ TR cells generated in the thymus perform
that role. In addition to regulation of autoimmune
responses, the T-cell response to foreign antigens must
be regulated as well. This regulation occurs in several
forms: activation induced cell death once antigen or co-
stimulation becomes limiting at the site of inflammation,
the production of cytokines that lead to inhibition of T-cell
responses, or the development of Tr1 or Th3 cells.
These regulatory phenomena are very important in the
resolution of inflammation, to rein in the T cell response, to
control bystander responses to self-antigens and to limit
the resulting T cells for future responses, so as to avoid
overwhelming immunologic reactions upon a repeated
exposure to an antigen. In addition, regulation of the
immune response may allow the fittest T cells to survive in
a nutrient-limiting environment in order to proceed to
become memory T cells. Evidence that this balancing act
involves both cytokines and CD4+CD25+ TR cells has
been found with cutaneous infection of mice with
Leishmania major, where the presence of TR cells leads to
a low-level persistence of the pathogen but allows for the
development of long-term immunity, whereas animals that
lack TR cells or IL-10 are able to completely clear the
infection but do not have any resistance to a second
infection [73].
As we have already described, TR cells may be generated
at the site of inflammation through the activation of
CD4+CD25– T cells, inducing the expression of FoxP3
and CD25. In this way, activation itself would lead to a
limitation of the extent to which the T-cell response could
proceed. It is not yet known whether the CD4+CD25–
T cells capable of differentiating into TR cells following
activation are derived from a separate lineage of CD4+
T cells, and whether their induction is a result of the initial
activation early in the inflammatory process or occurs late
upon depletion of growth signals (e.g. cytokines) in the
local environment. We propose that these cells act by
inhibiting further proliferation of T cells as the inflammatory
process has peaked and nutrients are limiting. This allows
a limited number of the most fit T cells to survive and
become memory cells, while the remaining T cell response
resolves through activation induced cell death (Fig. 1). In
addition, CD4+CD25+ TR cells leading to ‘infectious
tolerance’, thus inducing the local induction of Th3 or Tr1
cells [74], extends this paradigm. The fate of the TR cells
induced at the site is not known — whether these cells
exist only transiently then die, whether they persist in the
body as TR cells, or whether they return to their previous
role as nonregulatory resting T cells remains unknown.
The balancing act required by the immune system to
attack foreign invaders, to retain memory for future
exposures to an antigen while reining in an inflammatory
response once the danger has passed, and to retain
tolerance to self probably combines many mechanisms
both centrally and in the periphery. Our understanding of
regulation is now expanding with the identification of
peripherally generated Tr1, Th3 and TR cells. The
implication is that these cells may play a role in human
disease. TR cells have been isolated from tumors and
could contribute to inadequacy of the immune response
against these tumors. While inflammatory disease such as
allergy and autoimmunity may occur when the T regulatory
response is inadequate, a lack of TR cell function has been
demonstrated in autoimmune polyglondular syndrome II
[75]. It is likely that more subtle defects in the generation
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of regulatory response in the periphery could lead to
manifestations of autoimmunity. Our ability to generate
such regulatory cells holds promise for the development of
new therapies to enhance regulation to treat autoimmune
disease. A better understanding of how these forces work
together will allow us to understand immunologic settings
where either the immune response is inadequate, such as
the response to tumors, or it is misdirected, as in the case
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Figure 1
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Activation also induces a subset of CD4+CD25– T cells to upregulate
CD25 and FoxP3 and acquire CD25+CD4+ (TR) cell function. These
cells may result from activation at the initiation of the response or, more
probably, as the response matures. As antigen and IL-2 is depleted,
effector T cells undergo activation induced cell death, TR cells lead to
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